Review paper
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Abstract
TP53, encoding the tumour-suppressor p53, is the most frequently mutated gene across all human cancers. Similar to other transcription factors, p53 has proved notoriously difficult to target therapeutically; to date, no p53-targeted therapies have entered the clinic. The diversity ofTP53 mutations, which can be categorized across a spectrum of different functional classes, is increasingly recognized as an additional challenge to developing...
Paper Details
Title
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Published Date
Sep 26, 2017
Volume
15
Issue
1
Pages
13 - 30